1Leite AF, Dos Santos Ogata F, de Melo NS, de Souza Figueiredo PT. Imaging findings of bisphosphonate-related osteonecrosis of the jaws: A critical review of the quantitative studies. Int J Dent 2014; 2014:784348. https://doi.org/10.1155/2014/784348.
10.1155/2014/784348
PubMed Google Scholar
2Tsuchimochi M, Kurabayashi T. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication). Jpn Dent Sci Rev 2019; 55(1): 1-4. https://doi.org/10.1016/j.jdsr.2018.11.004.
10.1016/j.jdsr.2018.11.004
PubMed Web of Science® Google Scholar
3Azzali E, Milanese G, Martella I, et al. Imaging of osteonecrosis of the femoral head. Acta Biomed 2016; 87(Suppl 3): 6-12.
PubMed Google Scholar
4Fu W, Liu B, Wang B, Zhao D. Early diagnosis and treatment of steroid-induced osteonecrosis of the femoral head. Int Orthop 2019; 43(5): 1083-1087. https://doi.org/10.1007/s00264-018-4011-y.
10.1007/s00264-018-4011-y
PubMed Web of Science® Google Scholar
5Mori M, Koide T, Matsui Y, Matsuda T. A case of early detection of bisphosphonate-related osteonecrosis of the jaw. Indian J Pharmacol 2015; 47(3): 334-335. https://doi.org/10.4103/0253-7613.157137.
10.4103/0253-7613.157137
PubMed Web of Science® Google Scholar
6Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65(12): 2397-2410. https://doi.org/10.1016/j.joms.2007.08.003.
10.1016/j.joms.2007.08.003
PubMed Web of Science® Google Scholar
7Bedogni A, Blandamura S, Lokmic Z, et al. Bisphosphonate-associated jawbone osteonecrosis: A correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105(3): 358-364. https://doi.org/10.1016/j.tripleo.2007.08.040.
10.1016/j.tripleo.2007.08.040
PubMed Google Scholar
8Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofac Surg 2022; 80(5): 920-943. https://doi.org/10.1016/j.joms.2022.02.008.
10.1016/j.joms.2022.02.008
PubMed Web of Science® Google Scholar
9 Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017; 35(1): 6-19. https://doi.org/10.1007/s00774-016-0810-7.
10.1007/s00774-016-0810-7
PubMed Web of Science® Google Scholar
10Fedele S, Bedogni G, Scoletta M, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 2015; 53(1): 13-17. https://doi.org/10.1016/j.bjoms.2014.09.001.
10.1016/j.bjoms.2014.09.001
PubMed Web of Science® Google Scholar

Volume57, Issue5

May 2023

Pages 1607-1610

Filename	Description
jmri28434-sup-0001-Supinfo01.docxWord 2007 document , 24 KB	Appendix S1 Supporting Information
jmri28434-sup-0002-Supinfo02.docxWord 2007 document , 24.8 KB	Appendix S2 Supporting Information
jmri28434-sup-0003-Supinfo03.docxWord 2007 document , 14.3 KB	Appendix S3 Supporting Information

Jaw Alterations MRI and Serum Levels of C-Terminal Type I Telopeptide in Patients With Osteoporosis and Osteopenia Being Treated With Bisphosphonates Without Clinical Evidence of Osteonecrosis: A Pilot Study

Supporting Information

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Jaw Alterations MRI and Serum Levels of C-Terminal Type I Telopeptide in Patients With Osteoporosis and Osteopenia Being Treated With Bisphosphonates Without Clinical Evidence of Osteonecrosis: A Pilot Study

Supporting Information

References

References

Related

Information